Alto Neuroscience, Inc. (NYSE:ANRO) Receives $20.00 Average PT from Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $20.00.

Several research firms have commented on ANRO. Stifel Nicolaus dropped their target price on Alto Neuroscience from $32.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Rodman & Renshaw downgraded shares of Alto Neuroscience from a "buy" rating to a "neutral" rating in a research report on Wednesday, October 23rd. Wedbush lowered shares of Alto Neuroscience from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $29.00 to $4.00 in a report on Wednesday, October 23rd. William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Finally, Robert W. Baird reduced their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ANRO. Franklin Resources Inc. increased its stake in shares of Alto Neuroscience by 95.3% in the 3rd quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company's stock valued at $13,965,000 after acquiring an additional 595,673 shares in the last quarter. Vanguard Group Inc. bought a new stake in Alto Neuroscience in the first quarter valued at $8,233,000. Jennison Associates LLC raised its holdings in shares of Alto Neuroscience by 80.3% during the third quarter. Jennison Associates LLC now owns 832,290 shares of the company's stock valued at $9,521,000 after purchasing an additional 370,612 shares during the period. Geode Capital Management LLC boosted its position in shares of Alto Neuroscience by 148.7% during the 3rd quarter. Geode Capital Management LLC now owns 469,988 shares of the company's stock worth $5,378,000 after purchasing an additional 281,018 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Alto Neuroscience by 123.7% in the 3rd quarter. State Street Corp now owns 236,857 shares of the company's stock valued at $2,710,000 after buying an additional 130,985 shares during the period.

Alto Neuroscience Price Performance

NYSE:ANRO traded down $0.02 during trading hours on Friday, hitting $3.81. The company's stock had a trading volume of 319,006 shares, compared to its average volume of 371,370. Alto Neuroscience has a twelve month low of $3.61 and a twelve month high of $24.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The stock has a fifty day simple moving average of $6.49 and a 200-day simple moving average of $10.07.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.05. As a group, equities analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.